RAS Peptide Profiles in Patients With Arterial Hypertension
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label, parallel-group study conducted at a single center in Switzerland.
Patients diagnosed with primary arterial hypertension requiring antihypertensive drug
Treatment as well as patients after a 4 week wash out period (Amendment 07/2016) will be
recruited at the University Hospital Basel, Switzerland. Subjects will be randomized to
either the angiotensin-converting enzyme inhibitor-, angiotensin receptor blocker-, calcium
channel blocker- or hydrochlorothiazide-treatment arm. Drug treatment follows current
guidelines issued by the European Society of Hypertension. Treatment-naive patients will be
started on an intermediate dose monotherapy (treatment period 1). In all patients who do not
reach blood pressure targets after 4 weeks, the dose of the monotherapy drug will be doubled
(high dose, treatment period 2). Sampling for the analysis of RAS peptide profiles,
measurement of drug concentrations in plasma and non-invasive hemodynamic measurements will
be done. A control group with 20 age and gender matched, healthy and normotensive subjects
will be recruited to establish the characteristics of the RAS peptide profiles in a
comparable but normotensive population.
Details
Lead Sponsor:
University Hospital Inselspital, Berne University Hospital, Basel, Switzerland